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1. Introduction 
Neurodegenerative disorders (NDG) are incurable, progressive and debilitating conditions 
resulting from progressive degeneration and death of nerve cells. They are among the most 
serious health problems faced by modern society. Most of these disorders become more 
common with advancing age, including Alzheimer's disease and Parkinson's disease. The 
burden of these neurodegenerative diseases is growing inexorably as the population ages, 
with incalculable economic and human costs. According to the Global Burden of Disease 
Study, a collaborative study of the World Health Organization, the World Bank and the 
Harvard School of Public Health, dementia and other neurodegenerative diseases will be the 
eighth cause of disease burden for developed regions in 2020 [1, 2]. Also, according to the 
WHO, neurodegenerative diseases will become the world’s second leading cause of death 
by 2050, overtaking cancer [2]. True, such estimates and predictions need to be taken with 
caution, but they definitely confirm that neurodegenerative diseases are of an increasing 
public concern. 
Most NDG diseases are characterized by the aggregation of intracellular proteins. Majority 
of neurodegenerative disorders occur sporadically and are believed to arise through 
interactions between genetic and environmental factors. Only a small minority belong to 
familial forms where certain disease occurs due to a mutation of the gene coding for the 
abnormally aggregating protein.  
We differentiate many types of NDG disease, but the lines that separate one from another 
are often unclear. For instance, symptoms such as motor impairment and dementia may 
occur in many different types of NDG disease. Motor impairment similar to that seen in 
Parkinson’s disease is not enough to rule out other diagnoses, especially when both motor 
and cognitive impairment are present. At the time being, there is no such diagnostic test that 
can clearly indicate the presence, absence, or category of a NDG disease. Individual 
diagnosis is based on clinical evaluation of the symptoms, with the exception of monogenic 
NDG diseases, such as Huntington's disease (HD). HD is a single gene disorder and cause is 
invariably trinucleotide expansion mutation [3].  
Definitive diagnosis of certain NDG diseases still relies on neuropathological evaluation. But 
it has been demonstrated that brain pathology can show marked overlap among the 
syndromes of age-related cognitive and motor impairment [4]. Also, previous research 
reports have shown that pathological markers do not always correlate optimally with 
clinical findings. Some individuals with extensive neuropathology may retain relatively 
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intact neurological function while others with less extensive pathology may be significantly 
impaired [5, 6]. The neuropathological findings may be the response to other antecedent 
disease processes and are not necessarily the cause of the underlying disease at the early 
disease stages. Later, as disease progresses, they probably contribute to disease progression 
in a positive feedback loop.  
Analysis of whole genome transcriptome in brain might give us insights into the disturbed 
pathways and processes involved in disease onset and progression. Many different 
mechanisms have been proposed to be dysregulated in NDG diseases. We collected all 
reported studies to date on brain transcriptome in Parkinson's disease, Alzheimer disease, 
Huntington disease and Down syndrome and performed an integrated meta-analysis.  
2. Background 
2.1 Common neurodegenerative disorders – Alzheimer and Parkinson disease 
Two most common neurodegenerative diseases, Parkinson's disease (PD) and Alzheimer 
disease(AD) are believed to be heterogeneous based on the causes - combination of genetic 
and environmental factors, vast variety in the age at onset, variability in leading symptoms 
and presenting clinical manifestations, disease progression and responses to different 
therapies employed. Definitive diagnosis of both, AD and PD still relies on a ‘gold standard’ 
post mortem neuropathological evaluation, although a number of clinical and 
neuropsychological tests are often employed when making a clinical diagnosis. AD is 
detected with approximately 85–90% accuracy and PD with approximaly 75% accuracy. The 
pathogenesis of both AD and PD are complex and still remain unexplained in worldwide 
research community. 
It has been recently estimated [7] that 24 million people have dementia worldwide and 
majority is attributable to AD. The authors emphasized the urgency of better understanding 
of pathophysiology of the disease in order to improve development of disease-modifying 
treatment. Due to the age-dependent incidence rate of AD and due to the population ageing, 
it is foreseen that more than 80 million people will have AD by 2040 [8]. It is a progressive 
neurologic disease affecting particularly cortical and hippocampal neurons, leading to their 
irreversible loss [9]. Major clinical signs and symptoms are progressive impairment in 
memory, judgment, decision making, orientation to physical surroundings, and language. 
The key pathological characteristics are neuronal loss, β amyloid containing extracellular 
senile plaques, and neurofibrillary tangles, which are composed of a hyperphosphorylated 
form of the microtubular protein tau.  
PD is the second most prevalent NDG disease after AD. According to available data of 
European Parkinson's Disease Association (EPDA), there are 6.3 million people with PD 
worldwide. Prevalence is age-dependent - there are approximately 0.5 to 1 percent of 
individuals with PD in the age group 65 to 69 years, and 1 to 3 percent of individuals with 
PD in the group of people older than 80 years [10]. Typical clinical sign is parkinsonism - 
resting tremor, bradykinesia, rigidity, and postural instability. Neuropathological 
characteristics are the loss of neurons in the substantia nigra and the presence of neuronal 
inclusions termed Lewy bodies and Lewy neurites whose main component is aggregated 
and phosphorylated alpha-synuclein [11].  
Important futuristic challenge in the management AD and PD remains the establishment 
of early diagnosis or even identification of individuals prior to the onset of dementia in 
AD or resting tremor in PD. This implicates advancement in understanding disease 
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pathogenesis and development of diagnostic approaches, including disease/process 
specific biomarkers. 
2.2 Huntington disease – A model of genetic neurodegenerative disorder 
Huntington disease is a late onset, single gene disorder and its cause is invariably 
trinucleotide expansion mutation, known for almost 2 decades [3]. Clinical characteristics of 
the disease include progressive motor impairment, cognitive decline and various psychiatric 
symptoms with the typical age of onset in the third to fifth decade. The disease is fatal after 
15-20 years of progressive neurodegeneration [12]. So far, no effective treatment has been 
available to cure the disease or to slow its progression. Hyperkinesias and psychiatric 
symptoms may respond well to pharmacotherapy, but neuropsychological deficits and 
dementia remain untreatable [13]. We are unable to predict the age at onset and to follow 
the disease progression over short time periods due to the unsensitivity of rating scales. 
Even more, no useful measures to follow response to symptomatic treatment over short time 
periods are known. In addition, in the presymptomatic period when preventive treatment 
and slowing of neurodegeneration might be most effective, we have no measures/markers 
to monitor those responses and benefits.  
Although the responsible gene and mutation were already identified and characterized in 
1993, the function of normal huntingtin and the mutation mechanism that leads to 
neurodegeneration are still not clear. Basic research has demonstrated that the pathogenesis 
of HD involves recruitment of multiple biochemical pathways like protein degradation, 
apoptosis, accumulation of misfolded mutated proteins, intracelular signaling, oxidative 
stress, mitochondrial involvement and in the last years also transcription [14, 15].  
2.3 Dementia and Down syndrome 
Dementia, common symptom of all three already mentioned neurodegenerative diseases is 
also a common symptom in individuals with Down syndrome (DS). Most of individuals 
with DS after about age of 30 have the characteristic plaques and neurofibrillary tangles, 
associated with AD. As in general population, the prevalence of AD in people with DS 
increases significantly with age. On the other hand, age-related cognitive decline and 
dementia in people with DS occurs 30–40 years earlier than in the general population, 
reaching almost 40% in the 50s [16]. Life expectancy of people with DS continues to increase 
and therefore, dementia is becoming an important issue.  
2.4 Biomarkers  
Research in the field of biomarkers is a rapidly growing and developing area in medicine. 
Everyday advances in genomic, proteomic, metabolomic and epigenomic knowledge and 
technologies have made their way also in the neuroscientific research area. Biomarkers are 
very important indicators of normal and abnormal biological processes. By definition, 
biological marker or biomarker is a characteristic that is objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention [17]. Despite the fact that enormous effort and 
extensive research have been concentrated on this area, there is still a major lack of 
biomarkers for diagnosis, progression monitoring, response to treatment evaluation, etc. in 
neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD) 
and Huntington's disease (HD). 
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Biomarkers have many valuable applications, such as identification of major 
neuropathological processes in specific disease, disease detection and monitoring of health 
status, early efficacy and safety evaluations in in vitro studies in tissue samples, in vivo 
studies in animal models, and early-phase clinical trials. They are invaluable as a diagnostic 
tool for identification of patients with a disease or abnormal condition, as a tool in staging 
the disease or classification of the extent of disease, as an indicator of disease prognosis and 
in predicting and monitoring of a clinical response to treatment. 
Biomarkers are of extreme relevance in chronic NDG diseases - there are no cures for these 
diseases, as neurons of the central nervous system cannot regenerate on their own after cell 
death or damage. Tremendous efforts have been made in recent years to identify the 
neuropathological, biochemical, and genetic biomarkers of these diseases aiming to establish 
the diagnosis in earlier stages, to survey the rate of progression, or response to treatment. 
Currently, the neuropathologic diagnosis is a gold standard, but it can only be made in the 
form of an autopsy after the patient’s death. On the other hand, biomarkers may improve 
the early diagnosis at a stage when disease-modifying therapies are likely to be most 
effective, the monitoring of disease progression and the efficacy of any therapeutic 
intervention [18]. 
2.5 Brain transcriptome in neurodegenerative disorders 
Many different research groups have tried to solve the neuropathophysiological puzzle in 
PD, AD, HD and DS. Human brain has been extensivelly studied using many approaches, in 
the last decade also variety of »omic« technologies. Whole-genome gene expression studies 
in brain of each of four diseases individually have shown changes in transcription of 
number of genes when compared to normal human brain.  
We investigated, reviewed and collected data from all reported studies to date on brain 
transcriptome in Parkinson's disease, Alzheimer disease, Huntington disease and Down 
syndrome and performed integrated meta-analysis.  
3. Methods 
In an attempt to present the alterations consistently reported by studies of brain 
transcriptome in neurodegenerative diseases, we initially searched for such reports in 
literature databases, then obtained raw and processed experimental data from microarray 
data repositories, after which we performed probe level meta-analyses of datasets 
originating from various studies. In addition, to reveal possible commonalities and shared 
pathways across various neurodegenerative diseases, we inspected the similarities and 
differences in gene expression dysregularities occurring in these conditions. 
3.1 Study inclusion 
Initially, we have searched Medline database (http://www.ncbi.nlm.nih.gov/pubmed) for 
reports from studies of interest using the search string (transcriptom* OR microarray OR 
profiling OR Affymetrix OR Agilent OR Illumina OR array) AND (Parkinson's disease OR 
Parkinsons disease OR Parkinson disease AND Alzheimer's disease OR Alzheimers disease 
OR Alzheimer disease OR dementia OR Down's syndrome OR Downs syndrome OR Down 
syndrome OR trisomy 21 OR Huntington's disease OR Huntingtons disease OR Huntington 
disease) to obtain the complete list of studies reporting results relating to transcriptional 
alterations in brain tissues affected by neurodegenerative processes.  
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As we were primarily interested in the studies with microarray experimental results accessible 
from biological repositories, we then searched Gene Expression Omnibus (GEO) repository 
(http://www.ncbi.nlm.nih.gov/geo/), ArrayExpress database (http://www.ebi.ac.uk/arrayexpress/) 
and Stanford Microarray database (http://smd.stanford.edu) for studies with data available in 
the raw or processed form. As most of the gene expression profiling experiments were 
performed on Affymetrix platform and to avoid difficulties due to different probe 
annotations utilized by different microarray manufacturers, only results from experiments 
performed on the Affymetrix U133 platform were included to facilitate further steps in 
probe level meta-analysis of microarray data. The detailed information on datasets included 
in the analyses may be observed in Table 1.  
3.2 Microarray data pre-processing and preparation for meta-analysis  
All the integration and statistical steps described were performed in R statistical environment 
version 2.13.1 (http://cran.r-project.org), using Bioconductor version 2.8 packages 
(available at http://bioconductor.org) [19]. Raw data from all microarray experiments listed 
in Table 1 was obtained directly from Gene Expression Omnibus (GEO) repository 
(http://www.ncbi.nlm.nih.gov/geo/) utilizing the GEOquery package for R [20, 21].  
Before the meta-analysis of data from selected studies was performed, all the datasets 
obtained in such manner were inspected for significant inter-array differences in 
distribution of probe intensities. For this reason, raw datasets were initially examined using 
arrayQualityMetrics package and where necessary the straightforward quantile 
normalization functions in the affyPLM package was utilized [30, 31]. Non-specific intensity 
and interquartile variation filters were applied using methods in genefilter package [19]. 
Log2 transformations were applied where discrepancies in data reporting format were 
observed.  
Data collections for each individual neurodegenerative disease were then merged using 
probeset annotations as the common denominator. Using this approach we avoided 
potential statistical issues originating from averaging probe intensity values to obtain a 
single mean intensity value for each gene, possibly disregarding distinct expression of 
different transcripts from the same gene.  
These steps resulted in generation of 4 separate data matrices, each carrying data for a single 
disease, originating from multiple studies – Alzheimer disease (AD), Down syndrome (DS), 
Huntington disease (HD) and Parkinson disease (PD) datasets.  
3.3 Meta-analysis  
Summarized differential expression of genes in each merged dataset was calculated using 
meta-analysis algorithms incorporated in the RankProd package for R [32]. RankProd uses a 
non-parametric statistical algorithm that facilitates detection of genes that are consistently 
highly ranked across microarray datasets originating from various microarray experiments 
in various studies perfomed on the same condition (ie. disease). As this approach is based 
on rank statistics in contrast to approaches requiring analyzing absolute intensity values, it 
allows for inclusion of data originating from different laboratories, differing platforms and 
potentially studies performed under differing conditions [32].  
For analyses of such multi-study data, RPadvance function was utilized in our analyses, 
with origin parameter set to account for data originating from number of different sources 
corresponding to the number of different originating study [32]. Here it is important to  
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Number of array 
experiments 
GEO 
Accession  
Disease 
name 
Platform Number 
of 
probesets*
Affected 
tissue 
Unaffected 
tissue 
Tissue Ref 
GSE5281 Alzheimer’s 
disease 
Affymetrix HG-
U133Plus2 
54,675 87 74 Entorhinal 
cortex 
Hippocampus 
Medial 
temporal gyrus 
Posterior 
cingulate cortex 
Primary visual 
cortex 
Superior frontal 
gyrus 
[22] 
GSE1297 Alzheimer’s 
disease 
Affymetrix 
HG-U133A 
22,283 22 9 Hippocampus [23] 
†GSE16759 Alzheimer’s 
disease 
Affymetrix HG-
U133Plus2 
54,675 4 4 Parietal lobe 
tissue 
[24] 
†GSE7307 
 
Parkinson’s 
disease 
Affymetrix HG-
U133Plus2 
54,675 22 45 Caudate  
Gloubus 
pallidum 
Putamen  
Substantia 
nigra 
Subthalamic 
nucleus  
Thalamus 
lateral nuclei  
Thalamus 
subthalamic 
nucleus 
NA‡ 
GSE8397 Parkinson’s 
disease 
Affymetrix HG-
U133A 
and 
Affymetrix HG-
U133B 
22,283 
and 
22,645 
29 
and 
29 
18 
and 
18 
Substantia 
nigra  
Frontal cortex 
[25] 
GSE7621 Parkinson’s 
disease 
Affymetrix HG-
U133Plus2 
54,675 16 9 Substantia 
nigra 
[26] 
GSE3790 Huntington’
s disease 
Affymetrix HG-
U133A 
and 
Affymetrix HG-
U133B 
22,283 
and 
22,645 
114 87 Cerebellum 
Frontal cortex 
Caudate 
nucleus 
[27] 
†GSE1397 Down 
syndrome 
Affymetrix 
HG-U133A 
22,283 9 9 Cerebrum 
Cerebellum 
Astrocyte 
samples 
[28] 
GSE5390 Down 
Syndrome 
Affymetrix 
HG-U133A 
22,283 7 8 Dorsolateral 
prefrontal 
cortex 
[29] 
* According to data obtained from the GEO site 
† The dataset included some microarray experiments not related to the scope of this study and those 
were omitted from the analyses 
‡ The study related to listed GEO entry was not yet published 
Table 1. Detailed information on studies included in meta-analysis 
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stress that we have faced the issue of multiple studies simultaneously reporting differential 
expression in several different anatomical brain parts. As we wanted to facilitate the 
discovery of differentially expressed genes in diseased tissue in comparison to control 
samples, we set the origin parameter to take into account these considerations and regard 
such data as originating from different sources, thereby avoiding comparisons of gene 
expression between different brain regions rather than between affected and unaffected 
samples. Afterwards, P-values and q-values were obtained by performing 100 permutation 
cycles of complete originating datasets. An arbitrary P-value cut-off for significance of 
differential gene expression was then set at P<0.05. 
3.4 Investigating intersections between datasets and gene set enrichment analyses  
Resulting ordered lists of differentially expressed probesets were subsequently investigated 
for overlap between AD, DS, HD and PD datasets. Top 1000 genes from each dataset were 
used and intersections between combinations of two, three and four datasets were obtained. 
Venn diagrams in the results section were produced using Venny utility available at 
http://bioinfogp.cnb.csic.es/tools/venny/index.html. Furthermore, to gain insight in functional 
properties of genes in the intersections, gene set enrichment analyses (GSEA) were performed, 
utilizing GOstats package for R and investigating significant (uncorrected p<0.05) over- or 
underrepresentation of GeneOntology (GO) and KEGG terms annotating genes occurring in 
the intersections [33-36]. Additionally, DAVID tool (http://david.abcc.ncifcrf.gov/) was used 
to reveal the functional annotation clusters related to intersecting genes [37]. Required 
annotation conversions were performed using the hgu133plus.db package from Bioconductor 
annotation package collection and using biomaRt package for R in combination with Ensembl 
Biomart service (http://www.biomart.org/) [38, 39].  
4. Results 
Alltogether, our data collection comprised of data from 9 whole-genome expression studies, 
performed on samples from 4 neurodegenerative conditions (AD, DS, HD and PD). 
Collectively, 200, 33, 201, and 186 microarray analysed samples were included in the 
investigations of AD, DS, HD and PD, respectively, which accounted for 620 separate 
experiments included overall. A slight predominance of experiments performed on case 
tissues was noted in most of the experiements with summary case:control ratio amounting 
to 1,2:1 (339 affected tissues and 281 unaffected tissues included). 
Separate analyses of datasets for each NDG disorder have revealed significant perturbances 
in expression profiles of several genes. When arbitrary permutation p-value cut-off was set 
at 0.05 for upregulated genes, 5701 probesets attained significance in the AD dataset, 3291 in 
DS dataset, 4174 in the HD dataset and 3043 in the PD dataset. In the downregulated gene 
group the p<0.05 significance was reached for 5496 probesets in the AD dataset, 2983 
probesets in the DS dataset, 4079 in the HD dataset and 3410 in the PD dataset. A detailed 
view of the distribution of significance values of the top 10,000 ordered differentially 
expressed genes may be observed in Figure 1 for each of the NDG disorders.  
The resulting numbers of significant results are inflated by the effect of multiple testing and 
therefore the q- values were also estimated as described in the article by Breitling et al [40]. 
The numbers of upregulated probesets with estimated q-values below 0.05 were 3775 for 
AD, 1496 for DS, 3182 for HD and 1894 for PD datasets. The numbers of downregulated 
probesets meeting this criterion were 3624 in AD, 652 in DS, 3065 in HD and 2541 probesets 
in the PD dataset.  
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Fig. 1. Distribution of significance estimations for differential expression in 4 
neurodegenerative disorders 
An extent of global perturbation of the transciptome may be compared, with AD displaying 
the greatest extent of differentially expressed genes (blue line) and DS displaying the lowest 
extent, especially in the case of genes displaying downregulation.  
4.1 Common patterns of differential expression in neurodegenerative disorders 
Comparisons of comformity between profiles of transcriptome perturbations in four 
neurodegenerative diseases was initially performed by inspecting lists of top 1000 DE 
(differentially expressed) probesets for each condition and subsequently obtaining 
probesets (and genes) found to be differentially expressed simultaneously in several 
conditions. 
The numbers of overlapping probesets may be observed in Figure 2. The largest overlap was 
observed between between the PD and HD lists, with altogether 338 (33.8%) upregulated 
and 267 (26.7%) downregulated genes differentially expressed in both conditions. Detailed 
overview of the extent of overlap between pairs of top DE gene list may be observed in 
Figure 3. A notable number of probesets was DE in all four conditions: 44 upregulated and 
16 downregulated as presented in Figure 2a and 2b.  
4.2 Comparative functional analyses of differential expression profile in 
neurodegenerative diseases 
Calculations of gene set enrichment profile of upregulated and downregulated sets of genes 
presented here, were performed using hypergeometric test in the GOstats package. The 
profiles of DE genes were first calculated for each disorder separately, and afterwards every 
intersection between combinations of four sets of DE genes was evaluated. 
Results of interests from separate GSEA analyses are presented in Table2(a-d) for top 1000 
downregulated DE gene sets (the data for upregulated GSEA are not shown). Several GO 
biological process annotations appeared in all of the four analyses, most notably terms 
related to synaptic transmission and to cognitive processes.  
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We have also investigated the extent of similarity of GSEA profiles across four diseases. Top 
200 enriched GO terms were inspected in each neurodegenerative disorder and compared 
for matching terms in pair with other three disorders. Greatest similarity was observed 
between GSEA terms annotating downregulated genes in all four disorders, which may be 
observed in more detail in Figure 4. As previously observed for overlapping genes, greatest 
overlap was observed between PD and HD GO profiles in the upregulated (40.0% overlap) 
and downregulated sets (59.5% overlap).  
 
  
Fig. 2. Number of probesets overlapping between four sets of top 1000 DE upregulated (2a) 
and of top 1000 DE downregulated (2b) genes 
Please note the abbreviations: Alzheimer disease (AD), Down syndrome (DS), Huntington 
disease (HD) and Parkinson disease (PD).  
 
  
Fig. 3. a) Pairwise overlaps between lists of top DE upregulated (in red) and downregulated 
genes (in blue). Color intensiy of each square is proportional to size of overlap between a 
pair of DE gene lists. b) Pairwise overlaps between lists of top DE upregulated (in red) and 
downregulated genes (in blue). Color intensiy of each square is proportional to the value of 
–logp value obtained by performing hypergeometric test 
www.intechopen.com
 Neurodegenerative Diseases – Processes, Prevention, Protection and Monitoring 
 
512 
GOBPID 
Accession 
P-value Count  
of genes 
annotated
Term 
GO:0007268 1,01E-10 61 synaptic transmission 
GO:0019226 1,49E-09 63 transmission of nerve impulse 
GO:0035637 1,49E-09 63 multicellular organismal signaling 
GO:0044282 2,61E-07 68 small molecule catabolic process 
GO:0051443 5,09E-07 17 positive regulation of ubiquitin-protein ligase activity 
GO:0019752 9,12E-07 70 carboxylic acid metabolic process 
GO:0009144 1,82E-06 46 purine nucleoside triphosphate metabolic process 
GO:0051438 5,03E-06 17 regulation of ubiquitin-protein ligase activity 
GO:0007017 9,55E-06 35 microtubule-based process 
GO:0007611 1,65E-05 18 learning or memory 
GO:0030330 4,23E-05 16 DNA damage response, signal transduction by p53 class mediator 
GO:0031398 4,70E-05 17 positive regulation of protein ubiquitination 
Table 2a Alzheimer disease (downregulated genes). GOBPID stands for GeneOntology 
biological process ID 
 
GOBPID 
Accession 
P-value Count  
of genes 
annotated 
Term 
GO:0007268 3,47E-37 90 synaptic transmission 
GO:0019226 2,02E-35 93 transmission of nerve impulse 
GO:0007267 5,12E-29 110 cell-cell signaling 
GO:0007399 8,47E-15 113 nervous system development 
GO:0007611 6,38E-13 25 learning or memory 
GO:0007610 1,09E-12 46 behavior 
GO:0050890 5,29E-12 25 cognition 
GO:0048666 2,05E-10 59 neuron development 
GO:0006836 2,24E-10 23 neurotransmitter transport 
GO:0006811 9,51E-10 73 ion transport 
GO:0001505 1,00E-09 21 regulation of neurotransmitter levels 
GO:0031175 3,23E-09 52 neuron projection development 
GO:0032940 9,52E-09 50 secretion by cell 
GO:0048667 1,66E-08 46 cell morphogenesis involved in neuron differentiation 
GO:0022008 3,13E-08 67 neurogenesis 
Table 2b Huntington’s disease (downregulated genes). GOBPID stands for GeneOntology 
biological process ID 
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GOBPID 
Accession 
P-value Count  
of genes 
annotated 
Term 
GO:0007268 4,16E-17 68 synaptic transmission 
GO:0051234 1,99E-16 229 establishment of localization 
GO:0019226 1,34E-15 70 transmission of nerve impulse 
GO:0035637 1,34E-15 70 multicellular organismal signaling 
GO:0006836 9,40E-14 29 neurotransmitter transport 
GO:0009259 8,03E-13 58 ribonucleotide metabolic process 
GO:0009144 1,47E-12 55 purine nucleoside triphosphate metabolic process 
GO:0007399 8,20E-11 115 nervous system development 
GO:0001505 8,41E-11 24 regulation of neurotransmitter levels 
GO:0072521 9,91E-11 69 purine-containing compound metabolic process 
GO:0007269 1,05E-10 20 neurotransmitter secretion 
GO:0006753 2,95E-10 73 nucleoside phosphate metabolic process 
GO:0009117 2,95E-10 73 nucleotide metabolic process 
GO:0007267 3,23E-10 82 cell-cell signaling 
GO:0015980 9,19E-10 39 energy derivation by oxidation of organic compounds 
Table 2c Parkinson’s disease (downregulated genes). GOBPID stands for GeneOntology 
biological process ID 
 
GOBPID 
Accession 
P-value Count  
of genes 
annotated 
Term 
GO:0048856 6,65E-11 173 anatomical structure development 
GO:0007267 2,83E-08 65 cell-cell signaling 
GO:0050877 6,86E-07 69 neurological system process 
GO:0050789 1,60E-06 318 regulation of biological process 
GO:0022008 3,01E-06 58 neurogenesis 
GO:0030182 3,71E-06 53 neuron differentiation 
GO:0007399 4,91E-06 82 nervous system development 
GO:0048839 8,26E-06 14 inner ear development 
GO:0009887 1,69E-05 42 organ morphogenesis 
GO:0007186 1,76E-05 41 G-protein coupled receptor protein signaling pathway 
GO:0051716 2,70E-05 194 cellular response to stimulus 
GO:0003001 4,34E-05 24 generation of a signal involved in cell-cell signaling 
GO:0010903 5,15E-05 3 negative regulation of very-low-density lipoprotein 
particle remodeling 
GO:0007268 7,44E-05 35 synaptic transmission 
GO:0048667 7,44E-05 35 cell morphogenesis involved in neuron differentiation 
GO:0007165 9,36E-05 165 signal transduction 
GO:0048666 1,73E-04 41 neuron development 
Table 2d Down’s syndrome (downregulated genes). GOBPID stands for GeneOntology 
biological process ID 
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Fig. 4. Pairwise comparison of GO terms between pairs of datasets representing four 
neurodegenerative diseases. Percentages were calculated by dividing the number of GO 
terms overlapping by the number of all GO terms included in the overlapping analysis 
(N=200). GO terms annotating upregulated genes are presented in shades of red color and 
those annotating downregulated genes in blue 
5. Conclusion 
We have shown that whole-genome transcription analysis might be useful for identification 
and clarification of pathophysiological mechanisms in neurodegenerative diseases. We have 
used innovative approach of comparing and integrating experiment results from different 
NDG diseases and provided new important insights into the common NDG processes. 
Elucidation of these mechanisms holds important potential for future prediction and 
development of new useful treatments as well as for identification of biomarkers of 
neurodegeneration.  
When comparisons of intersections between groups of top DE genes were performed, the 
greatest overlap was found between DE genes in brain samples of patients with HD and PD, 
which is possibly in accordance with their primary manifestation in movement disturbances 
related to function of basal ganglia. On the other hand, this similarity is surprising, as the 
known etiological agents in HD and PD differ significantly, one disorder being a 
consequence of monogenic disruption and other being a complex disorder with 
heterogeneous combination of genetic and environmental factors [41]. Surprisingly high is 
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also the profile overlap between AD and PD, which present as clinically somewhat distinct 
entities. Recently however, it has been becoming progressively more obvious that the two 
disorders share not only a significant proportion of clinical elements (movement disorder, 
cognitive decline, mood and psychiatric disorders) but also share common 
pathophysiological pathways [42]. These results potentially suggest that clinical distinction 
between disease entities may not be perfect projection of actual processes at cellular and 
molecular level. Additionally, in contrast to expectation, however, the lowest overlap was 
observed between samples from patients with DS and AD, especially as these conditions 
have been known to share NDG pathways related to amyloid beta deposition in neurons. 
Reasons for lower extent of overlap may be found in significant differences in the age of 
patients from whom the brain samples were obtained for studies of DS in comparison with 
AD. Additionally, it is important that in most instances, a complete triplication of genes 
located on chromosome 21 may dominate genes commonly dysregulated in DS and AD [29]. 
Also, the number of brain tissue samples samples profiled in microarray experiments was 
by far the lowest among other types of NDG diseases investigated in our survey. Therefore, 
before final answer regarding this finding is obtained, more studies investigating 
transcriptional alterations in DS brain samples must be performed.  
Several GO categories appeared to be consistently singled out in GSEA analyses of separate 
and overlapping genes DE in NDG disorders. Interestingly several terms were related to 
processes previously associated with neuron degeneration [42], most prominently GO 
terms: synaptic transmission (GO:0007268), neurogenesis (GO:0022008) and terms related to 
higher cognitive processes (GO:0007611). Dysfunctional synaptic transmission (as in 
glutamate exitotoxicity) and defects in neurogenesis have been previously repeatedly shown 
to be related to various NDG diseases [42-44]. It is interesting that although disturbances in 
neuroinflammatory mechanisms have been proposed as a possible causative factor in a 
number of NDG diseases, our analysis of intersecting genes dysregulated in brain samples 
of these conditions did not single out a particular common inflammatory pathogenetic 
pathway. This notion may be interpreted in the light of previously recognized differences in 
complement-activating immunogenic activity of plaques in different NDG diseases, 
resulting in absence of commonly overlapping inflammatory genes and GO terms [42].  
When we investigated the compatibility of functional profiles between four NDG diseases, 
we have found greatest overlaps between sets of GO terms annotating genes characterized 
by downregulation in NDG diseases, where an overlap greater than 40% was observed in all 
of the pairwise comparisons of the sets of top 200 enriched GO terms. Again, the greatest 
functional conformance was noted between top downregulated genes in HD and PD as well 
as AD and PD dataset pairs. Notable overlap was also observed in the functional profiles of 
upregulated genes, where we noted good functional conformity between DS and HD 
datasets in addition to HD-PD and AD-PD functional overlaps.  
It is important to stress that genome-wide expression studies included in this survey are 
inherently burdened by important statistical issues that predominantly originate from the 
issue of testing a large number of variables on a relatively small population of biological 
replicates (ie. study subjects) [45]. For this reason we attempted to gain a more complete 
account of biological alterations in neurodegenerative diseases by merging data from 
several different studies investigating transcriptional changes in brain samples of distinct 
neurological conditions (AD, DS, HD and PD) [46]. This increased the number of biological 
replicates considerably, allowing for potentially more reliable calling of DE genes in these 
conditions. There are, however, important downsides to this approach: the studies included 
www.intechopen.com
 Neurodegenerative Diseases – Processes, Prevention, Protection and Monitoring 
 
516 
were performed under differing conditions in different institutions and by different research 
staff. Even more important is the great heterogeneity between brain tissue samples 
investigated. We have attempted to circumvent these issues by using appropriate RankProd 
meta-analysis methods, nevertheless these results must be interpreted in light of these 
considerations.  
Nevertheless it is still difficult to differentiate between the causal changes in transcriptome 
in contrast to changes resulting from previous damage to neural tissue. It is possible, 
however, that the similarities in transcriptome profile between clinically and pathologically 
distinct entities suggest a common response to an unknown initial damaging stimulus. We 
propose that in future, integration of various data such as genomic in combination with 
transcriptomic data should provide a way to delineate possible mechanisms, where genetic 
predisposition results in manifestation of transcriptional imbalances, consequently resulting 
in observed phenotype. Genome-wide expression profiling may however direct further 
research attempts into a particular direction. Also, there are other “omics” approaches 
besides transcriptomics and integrating all of them is future challenge. 
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